Literature DB >> 18040242

Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).

Iryna A Falkenstein1, Lingyun Cheng, William R Freeman.   

Abstract

PURPOSE: To determine changes and need to monitor intraocular pressure (IOP) following intravitreal injection of bevacizumab (Avastin).
METHODS: Seventy patients (122 injections) underwent an intravitreal injection of Avastin for exudative age-related macular degeneration treatment. Forty-one eyes (59%) had single injection, 29 eyes (41%) had repeated injections. IOP was measured before and after Avastin injection at 3, 10, and 15 minutes. Twenty-nine eyes were evaluated for baseline IOP changes after multiple injections. Statistical analysis was performed.
RESULTS: Baseline mean IOP was 15.17 +/- 3.42 mm Hg, with range from 08 mm Hg to 23 mm Hg. Postinjection 3 minutes the IOP had risen to a mean of 36.27 +/- 5.1 mm Hg and fell spontaneously to a mean of 24.56 +/- 5.9 mm Hg at 10 minutes. Ten eyes (14%) needed 15 minutes to drop below 30 mm Hg. All eyes were below 30 mm Hg at 15 minutes. No significant change between multiple baseline IOP measurements was detected.
CONCLUSION: Avastin injections caused a predictable probably volume-related rise in IOP which never occluded the central retinal artery and which spontaneously fell to below 30 mm Hg in all eyes within 15 minutes. This strong safety profile provides guidelines on monitoring IOP after Avastin injections. There was no IOP change after multiple injections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040242     DOI: 10.1097/IAE.0b013e3180592ba6

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  45 in total

1.  Management of non-arteritic anterior ischemic optic neuropathy.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12       Impact factor: 3.117

2.  Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF.

Authors:  M Gómez-Mariscal; B Puerto; F J Muñoz-Negrete; V de Juan; G Rebolleda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-06-28       Impact factor: 3.117

3.  Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.

Authors:  Masoud Soheilian; Saeed Karimi; Talieh Montahae; Homayoun Nikkhah; Seyed Aliasghar Mosavi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-14       Impact factor: 3.117

4.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.

Authors:  Güngör Sobacı; Rıza Güngör; Gökhan Ozge
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

5.  Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.

Authors:  Sibel Demirel; Ozge Yanik; Figen Batioglu; Emin Ozmert
Journal:  Int Ophthalmol       Date:  2014-07-31       Impact factor: 2.031

6.  Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.

Authors:  C D Murray; D Wood; V Allgar; G Walters; R P Gale
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

7.  Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.

Authors:  Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2017-01-17       Impact factor: 1.402

Review 8.  [Dynamic Scheimpflug Analyzer (Corvis ST) for measurement of corneal biomechanical parameters : A praxis-related overview].

Authors:  R Herber; N Terai; K R Pillunat; F Raiskup; L E Pillunat; E Spörl
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

9.  Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.

Authors:  Andrea Cacciamani; Francesco Oddone; Mariacristina Parravano; Fabio Scarinci; Marta Di Nicola; Giorgio Lofoco
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

10.  Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial.

Authors:  D B Rootman; H S Gill; E A Margolin
Journal:  Eye (Lond)       Date:  2013-02-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.